drugset / Trial / NCT06663007
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Non-randomizedSingle-groupSingle-blindTreatment
Summary
The aim of this study is to evaluate the efficacy and safety of vediximab monotherapy or in combination with enrolizumab for second-line treatment of CDK12 alterations mCRPC that has failed standard therapy. The research results are expected to provide new insights and breakthroughs for the treatment of advanced prostate cancer.
Timeline
- Start
- 2024-09-24
- Primary completion
- 2027-05-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Envafolimab | Monoclonal antibody | 400 mg | Subcutaneous |